Prices for COVID-19 Vaccines, Drugs Could Consider Value
Payers shouldn’t write off the idea of value-based pricing for COVID-19 vaccines and therapeutics, even though the ongoing coronavirus pandemic makes it imperative to develop and release those products as quickly as possible, four Tufts Medical Center researchers say.
The researchers, writing in the January edition of Health Affairs, say payers should consider value from both a health system and a societal perspective.
© 2023 MMIT